gms | German Medical Science

Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

15.09. - 18.09.2021, virtuell

Artikel

Artikel empfehlen

Long-term outcomes of treatment according to treat-to-target strategy at early stage of psoriatic arthritis – preliminary results

Meeting Abstract

Suche in Medline nach

  • Polina Tremaskina - V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow
  • Elena Loginova - V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow
  • Tatiana V. Korotaeva - V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). sine loco [digital], 15.-18.09.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocSpA.50

doi: 10.3205/21dgrh165, urn:nbn:de:0183-21dgrh1654

Veröffentlicht: 14. September 2021

© 2021 Tremaskina et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Introduction: Treatment according to treat to target (T2T) concept at an early stage of psoriatic arthritis (PsA) confirmed the benefit [1]. Nevertheless, the long-term outcomes of using the T2T have not been presented yet.

Objectives: To assess 5 years (yrs) follow-up of PsA patients (pts) treated according to T2T strategy at the early stage of disease.

Methods: This study assessed 37 (M/F–18/19) PsA pts according to CASPAR criteria, mean age 43.3±11.7 yrs, median (Me) PsA duration 72 [60;90] month (mos), psoriasis duration 120 [88;180] mos, who were treated according to T2T at the early stage within 24 mos. All pts underwent standard clinical examination. Within 24 mos of T2T strategy all pts were taking Methotrexate (MTX) monotherapy at a dose of 20-25 mg/wk. When T2T study was stopped all pts were treated according to the standard care based on a PsA activity. Comparative analyses of PsA activity by DAPSA were calculated at the 24 mos of T2T strategy and at 5 yrs follow-up. M±SD, Me [Q25; Q75] were performed.

Results: At the early stage of PsA, before started treatment with MTX, Me DAPSA was 30 [20.75;56.5]. At 24 mos Me DAPSA 11 [3;36.75], remission by DAPSA (REM-DAPSA) were seen in 20 out of 37 (54%) pts, LDA-DAPSA in 5 (14%) pts, moderate activity (MoA) by DAPSA in 6 (16%) pts and high disease activity by DAPSA (HDA-DAPSA) in 6 (16%) pts. At 5 yrs Me DAPSA 17 [6;34.35], REM-DAPSA was noted in 13 (35%) pts, LDA-DAPSA in 13 (35%), MoA-DAPSA in 5 (14%), HDA-DAPSA in 6 (16%) pts.

Conclusion: The T2T strategy has been proven to be effective in PsA treatment. Further evaluations of the long-term outcomes of T2T strategy in PsA are required.

Disclosures: None declared

Gliederung

References

1.
Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, Meads DM, Emery P, Conaghan PG, Helliwell PS. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015 Dec;386(10012):2489-98. DOI: 10.1016/S0140-6736(15)00347-5 Externer Link